INT127890

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.50
First Reported 2005
Last Reported 2007
Negated 0
Speculated 0
Reported most in Body
Documents 6
Total Number 6
Disease Relevance 1.41
Pain Relevance 0.45

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cytosol (CYP19A1) small molecule metabolic process (CYP19A1) endoplasmic reticulum (CYP19A1)
cytoplasm (CYP19A1)
Anatomy Link Frequency
oocytes 2
CYP19A1 (Homo sapiens)
Pain Link Frequency Relevance Heat
Bioavailability 3 89.40 High High
cINOD 6 71.20 Quite High
COX2 3 25.00 Low Low
cOX1 1 25.00 Low Low
transdermal 1 20.08 Low Low
antagonist 132 5.00 Very Low Very Low Very Low
agonist 104 5.00 Very Low Very Low Very Low
corticosteroid 24 5.00 Very Low Very Low Very Low
endometriosis 21 5.00 Very Low Very Low Very Low
dexamethasone 15 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Metastasis 7 95.20 Very High Very High Very High
Breast Cancer 30 92.60 High High
Cancer 36 88.56 High High
Arthralgia 10 83.08 Quite High
Hypersensitivity 2 73.12 Quite High
Breast Disease 3 68.16 Quite High
INFLAMMATION 5 65.04 Quite High
Reprotox - General 3 116 62.56 Quite High
Polycystic Ovary Syndrome 36 61.44 Quite High
Reprotox - General 1 51 56.56 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Treatment with COX-2 siRNAs decreased the expression of COX-2 mRNA; furthermore, the siCOX-2-mediated decrease also resulted in suppression of CYP19 mRNA.
Positive_regulation (resulted) of Negative_regulation (suppression) of CYP19
1) Confidence 0.50 Published 2007 Journal J. Steroid Biochem. Mol. Biol. Section Abstract Doc Link 17616393 Disease Relevance 0.39 Pain Relevance 0.13
Finally, treatment with COX-2 siRNAs downregulated the expression of COX-2 mRNA; furthermore, the siCOX-2-mediated suppression of COX-2 also resulted in suppression of aromatase mRNA.
Positive_regulation (resulted) of Negative_regulation (suppression) of aromatase mRNA
2) Confidence 0.50 Published 2005 Journal J. Steroid Biochem. Mol. Biol. Section Abstract Doc Link 15964185 Disease Relevance 0.34 Pain Relevance 0.24
The novel idea of using aromatase inhibitors during ovarian stimulation for assisted reproduction combines the benefit of a significant reduction in estrogen production as well as gonadotropins dose, with the exiting advantage of achieving a good number of mature oocytes as a result of enhanced ovarian response to gonadotropins.
Positive_regulation (using) of Negative_regulation (inhibitors) of aromatase in oocytes
3) Confidence 0.39 Published 2005 Journal Reprod Biol Endocrinol Section Body Doc Link PMC1266397 Disease Relevance 0 Pain Relevance 0
We hypothesized that significantly higher concentration of the aromatase inhibitor can be achieved early in the menstrual cycle with faster clearance later in the menstrual cycle with the administration of a high single dose of the aromatase inhibitor early in the menstrual cycle such as on day 3.
Positive_regulation (concentration) of Negative_regulation (inhibitor) of aromatase
4) Confidence 0.39 Published 2005 Journal Reprod Biol Endocrinol Section Body Doc Link PMC1266397 Disease Relevance 0 Pain Relevance 0.04
Developing alternative regimens for administering aromatase inhibitors for ovarian stimulation
Positive_regulation (administering) of Negative_regulation (inhibitors) of aromatase
5) Confidence 0.39 Published 2005 Journal Reprod Biol Endocrinol Section Body Doc Link PMC1266397 Disease Relevance 0.12 Pain Relevance 0.04
Overcoming resistance to aromatase inhibitors
Positive_regulation (resistance) of Negative_regulation (inhibitors) of aromatase
6) Confidence 0.23 Published 2007 Journal International Journal of Clinical Practice Section Body Doc Link PMC2228389 Disease Relevance 0.55 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox